Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
HOYA Corporation (7741.T)
Tokyo, JP
Globally recognized as a med-tech innovator, HOYA Corporation is a prominent provider of advanced technology and healthcare solutions worldwide. Its comprehensive portfolio of life care products encompasses vision correction items such as eyeglasses and contact lenses, alongside sophisticated medical devices including endoscopes, intraocular lenses, and surgical instruments for laparoscopic procedures. HOYA also supplies automated endoscope cleaning systems and various medical essentials like prosthetic ceramic fillers and metallic implants. Complementing its medical offerings, the company operates Eyecity, a specialized retail chain for contact lenses. In the realm of information technology, HOYA manufactures crucial components such as mask blanks and photomasks for semiconductor and liquid crystal display fabrication, as well as glass disks for hard disk drives. Its imaging products segment includes optical glasses, specialized lenses, colored glass filters, and laser/UV light source equipment. Furthermore, the company extends its expertise into software and cloud services, offering ReadSpeaker, a speech synthesis application, and cloud platforms like Kinnosuke for time and attendance management, and Yonosuke for electronic payslip distribution. HOYA Corporation, established in 1941, is headquartered in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.61% | -1.95% | -5.99% | -2.58% | +13.09% | +14.95% | +56.37% | +81.21% | +115.26% | +596.43% | +1,220.24% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 10 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+9.4% ★ Q1'26: +14.5% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+28.0% ★ Q1'26: +7.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+16.5% Q1'26: +26.3% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+29.6% ★ Q1'26: +29.7% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+42.8% ★ Q1'26: +40.7% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-2.1% ★ Q1'26: -2.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.12× ★ Q1'26: 0.12× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 15 Rev. Ana. 15 EPS Ana. |
Mar 2027 14 Rev. Ana. 13 EPS Ana. |
Mar 2028 14 Rev. Ana. 14 EPS Ana. |
Mar 2029 8 Rev. Ana. 8 EPS Ana. |
Mar 2030 4 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
489.96B
est: 488.81B (+0.2%)
|
505.71B
est: 512.06B (-1.2%)
|
478.93B
est: 477.26B (+0.3%)
|
535.61B
est: 533.16B (+0.5%)
|
565.81B
est: 566.84B (-0.2%)
|
576.55B
est: 579.14B (-0.4%)
|
547.92B
est: 543.06B (+0.9%)
|
661.47B
est: 656.03B (+0.8%)
|
723.58B
est: 715.69B (+1.1%)
|
762.61B
est: 794.10B (-4.0%)
|
866.03B
est: 870.20B (-0.5%)
|
939.19B
920.79B – 962.32B
+7.9% YoY
|
1.02T
991.23B – 1.05T
+8.5% YoY
|
1.10T
1.05T – 1.14T
+7.8% YoY
|
1.18T
1.18T – 1.18T
+7.8% YoY
|
1.29T
1.25T – 1.33T
+9.0% YoY
|
| EBITDA |
154.19B
est: 180.05B (-14.4%)
|
153.53B
est: 188.61B (-18.6%)
|
141.65B
est: 175.80B (-19.4%)
|
153.63B
est: 196.39B (-21.8%)
|
171.43B
est: 208.79B (-17.9%)
|
182.21B
est: 213.32B (-14.6%)
|
196.57B
est: 200.03B (-1.7%)
|
254.48B
est: 241.65B (+5.3%)
|
266.20B
est: 263.62B (+1.0%)
|
284.45B
est: 292.27B (-2.7%)
|
309.48B
est: 320.28B (-3.4%)
|
345.67B
338.90B – 354.19B
+7.9% YoY
|
375.01B
364.83B – 385.58B
+8.5% YoY
|
404.20B
388.00B – 418.74B
+7.8% YoY
|
435.58B
435.44B – 435.72B
+7.8% YoY
|
474.69B
458.62B – 489.98B
+9.0% YoY
|
| EBIT |
119.34B
est: 148.97B (-19.9%)
|
120.01B
est: 156.06B (-23.1%)
|
111.88B
est: 145.45B (-23.1%)
|
124.90B
est: 162.49B (-23.1%)
|
144.99B
est: 172.75B (-16.1%)
|
147.82B
est: 176.50B (-16.3%)
|
160.24B
est: 165.50B (-3.2%)
|
211.46B
est: 199.93B (+5.8%)
|
216.58B
est: 218.11B (-0.7%)
|
237.23B
est: 242.55B (-2.2%)
|
260.90B
est: 265.80B (-1.8%)
|
286.87B
281.25B – 293.94B
+7.9% YoY
|
311.22B
302.77B – 319.99B
+8.5% YoY
|
335.44B
322.00B – 347.51B
+7.8% YoY
|
361.49B
361.37B – 361.61B
+7.8% YoY
|
393.94B
380.61B – 406.63B
+9.0% YoY
|
| Net Income |
92.80B
est: 76.06B (+22.0%)
|
93.18B
est: 80.73B (+15.4%)
|
86.74B
est: 79.62B (+8.9%)
|
99.49B
est: 94.51B (+5.3%)
|
122.10B
est: 111.64B (+9.4%)
|
114.41B
est: 114.40B (+0.0%)
|
125.45B
est: 117.10B (+7.1%)
|
164.51B
est: 155.32B (+5.9%)
|
168.64B
est: 162.37B (+3.9%)
|
181.38B
est: 190.32B (-4.7%)
|
202.10B
est: 206.78B (-2.3%)
|
253.09B
225.85B – 265.55B
+22.4% YoY
|
263.73B
260.38B – 278.38B
+4.2% YoY
|
297.43B
288.92B – 321.95B
+12.8% YoY
|
344.39B
327.02B – 361.76B
+15.8% YoY
|
420.35B
401.85B – 437.95B
+22.1% YoY
|
| SGA |
187.88B
est: 166.96B (+12.5%)
|
195.02B
est: 174.90B (+11.5%)
|
179.61B
est: 163.02B (+10.2%)
|
201.78B
est: 182.11B (+10.8%)
|
204.00B
est: 193.61B (+5.4%)
|
195.85B
est: 197.81B (-1.0%)
|
175.92B
est: 185.49B (-5.2%)
|
213.04B
est: 224.08B (-4.9%)
|
245.04B
est: 244.46B (+0.2%)
|
276.64B
est: 298.71B (-7.4%)
|
314.65B
est: 327.34B (-3.9%)
|
353.29B
346.37B – 361.99B
+7.9% YoY
|
383.27B
372.86B – 394.07B
+8.5% YoY
|
413.10B
396.55B – 427.97B
+7.8% YoY
|
445.17B
445.03B – 445.32B
+7.8% YoY
|
485.14B
468.72B – 500.77B
+9.0% YoY
|
| EPS |
218.23
est: 218.74 (-0.2%)
|
225.45
est: 232.18 (-2.9%)
|
221.93
est: 228.99 (-3.1%)
|
258.46
est: 271.83 (-4.9%)
|
321.55
est: 321.09 (+0.1%)
|
303.27
est: 329.02 (-7.8%)
|
335.77
est: 336.80 (-0.3%)
|
446.45
est: 446.72 (-0.1%)
|
469.76
est: 466.99 (+0.6%)
|
515.27
est: 542.23 (-5.0%)
|
581.45
est: 586.42 (-0.8%)
|
733.26
663.78 – 780.46
+25.0% YoY
|
792.54
765.26 – 818.14
+8.1% YoY
|
897.43
849.13 – 946.21
+13.2% YoY
|
1,010.76
961.12 – 1,063.21
+12.6% YoY
|
1,235.40
1,181.04 – 1,287.15
+22.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-01 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Eiichiro Ikeda | Representative Executive Officer, President, Chief Executive Officer & Chairperson of Board of Directors | 266M | male |
| Ryo Hirooka | Representative Executive Officer, Chief Financial Officer & Director | 158M | male |
| Tomoko Nakagawa | Executive Officer & Chief Sustainability (ESG) Officer | 112M | female |
| Taishi Arashida | Officer of IR | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7741.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
